NCT06705504
- Conditions
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- Locations
-
- Novartis East Hanover, New Jersey, United States
Clinical trial condition
Hormone Receptor Positive HER-2 Negative Breast Cancer
Explore clinical trials studying Hormone Receptor Positive HER-2 Negative Breast Cancer. Study availability and eligibility vary by location and protocol.
13 public trials
8 recruiting studies
Hormone Receptor Positive HER-2 Negative Breast Cancer trial results
Completed
Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer
NCT02692755
- Conditions
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- Locations
-
- MedStar Georgetown University Hospital Washington D.C., District of Columbia, United States
- MedStar Washington Hospital Center Washington D.C., District of Columbia, United States
- University of Chicago Chicago, Illinois, United States
- MedStar Union Memorial Hospital Baltimore, Maryland, United States
Active, Not Recruiting
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
NCT06257264
- Conditions
- Adnexal Diseases, Advanced Solid Tumor, Bladder Cancer, +55 more
- Locations
-
- Hoag Memorial Presbyterian Newport Beach, California, United States
- Florida Cancer Specialists and Research Institute Lake Mary, Florida, United States
- Washington University School of Medicine St Louis, Missouri, United States
- Titan Health Partners Llc Dba Astera Cancer Care East Brunswick, New Jersey, United States